82 results on '"West, Michael L."'
Search Results
2. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort
3. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
4. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
5. Chest pain subtype prevalence in the British Columbia cohort of the Canadian Fabry Disease Initiative
6. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion
7. Switch from enzyme replacement therapy to pharmacologic chaperone: Improvement in advanced Fabry nephropathy
8. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
9. Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy
10. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD)
11. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years
12. Clinical characteristics of female patients enrolled in the FollowME Fabry Pathfinders registry
13. Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
14. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey
15. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
16. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis
17. Persistent Hematopoietic Polyclonality after Lentivirus-mediated Gene Therapy for Fabry Disease
18. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
19. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
20. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
21. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
22. Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up
23. Lentivirus-mediated gene therapy for Fabry disease
24. Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype
25. Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group
26. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
27. Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report
28. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
29. Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
30. Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
31. Routes to diagnosis of Fabry disease according to patient age and geographic distribution
32. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism
33. Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report
34. Determination of the crystal structure and substrate specificity of ananain
35. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
36. Solid-Phase Oligosaccharide Chemistry and Its Application to Library Synthesis
37. FP114RENOPROTECTIVE EFFECT OF AGALSIDASE ALFA IN FABRY DISEASE IS INDEPENDENT OF TYPE OF MUTATION: RESULTS OF 12-YEAR FOLLOW-UP
38. Valvular heart disease complicating advanced Fabry disease: Association with chronic kidney disease
39. FACTs Fabry gene therapy clinical trial: Two-year data
40. Renal and cardiac outcomes in female patients with Fabry disease treated with agalsidase beta: A Fabry registry analysis of pre- versus post-treatment comparison
41. Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
42. Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
43. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
44. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
45. Prevalence of Fabry Disease and Outcomes in Young Canadian Patients With Cryptogenic Ischemic Cerebrovascular Events
46. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease
47. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
48. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
49. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
50. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.